Who founded ResistanceBio?

ResistanceBio was founded by Nicholas Goldner, Christopher Bulow in 2016.

Who are ResistanceBio's investors?

ResistanceBio's investors include Fifty Years, Y Combinator, NFX.

How much funding has ResistanceBio raised?

ResistanceBio has disclosed $12.8M raised across 1 round.

Where is ResistanceBio headquartered?

ResistanceBio is headquartered in San Francisco, US.

ResistanceBio

DefunctYC W19

San Francisco, US · Founded 2016 · Delaware corporation · 15 employees · 3 known investors

ResistanceBio develops treatments to address drug resistance in cancer patients.

Also known as Viosera Therapeutics

Biotech Healthtech AI-powered Drug DiscoveryUnited States of AmericaAmerica / CanadaPartly Remote

Founders & leadership· Y Combinator alumni (W19)

ResistanceBio was founded in 2016 by Nicholas Goldner and Christopher Bulow.

Nicholas Goldner inFounder2021–2024Nicholas Goldner holds a PhD in molecular cell biology and has expertise in cellular adaptation mechanisms. He applies this background to company building and project evaluation.

Christopher Bulow inCTO, Co-Founder2023–2024Christopher Bulow founded Viosera Therapeutics, which developed antimicrobial drugs, and subsequently founded ResistanceBio to address drug resistance challenges in cancer treatment for pharmaceutical companies.

KYLE LAPHAMNamed on SEC filing

Board

OMRI AMIRAV-DRORY in 𝕏Board Member2022–2024General Partner at NFX

Investors · 3

Fifty YearsSan Francisco · $250K – $2M

Y CombinatorSan Francisco · $500K

NFXreported · 2 sourcesSan Francisco · $250K – $5Mvia Omri Amirav Drory · board

Reported raises · per SEC filings

Form D private placements

$12.8M disclosed across 1 round · 2024

▶$12.8MraisedJan 2024 · 44 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

NICHOLAS GOLDNERExecutive Officer, Director
KYLE LAPHAMExecutive Officer, Director
OMRI AMIRAV-DRORYDirector
CHRISTOPHER BULOWExecutive Officer, Director

Offering amount: $12.8M
Amount sold: $12.8M
Minimum investment: $1
First sale: Jan 2024
Incorporated: Corporation, Delaware, 2021
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

What is Brief History of resistanceBio Company? – businessmodelcanvastemplate.comcanvasbusinessmodel.com · Dec 2024

Frequently asked questions

What does ResistanceBio do?: ResistanceBio develops treatments to address drug resistance in cancer patients.
Who founded ResistanceBio?: ResistanceBio was founded by Nicholas Goldner, Christopher Bulow in 2016.
Who are ResistanceBio's investors?: ResistanceBio's investors include Fifty Years, Y Combinator, NFX.
How much funding has ResistanceBio raised?: ResistanceBio has disclosed $12.8M raised across 1 round.
Where is ResistanceBio headquartered?: ResistanceBio is headquartered in San Francisco, US.